CONTACT-02: Cabozantinib Plus Atezolizumab in mCRPC

Opinion
Video

Following ASCO GU 2024, Tian Zhang, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from CONTACT-02 investigating cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer.

Related Videos
Related Content